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Summary 
 
Somatic rearrangements contribute to the mutagenized landscape of cancer 
genomes. Here, we systematically interrogated rearrangements in 560 breast 
cancers using a piecewise-constant fitting approach. We highlight 33 hotspots 
of large (>100kb) tandem duplications, a mutational signature associated 
with Homologous Recombinational repair deficiency. Remarkably, these tandem 
duplication hotspots are enriched for breast cancer germline susceptibility loci 
(OR 4.28) and breast-specific “super-enhancer” regulatory elements (OR 3.54). 
They could represent sites of selective susceptibility to double-strand break 
damage due to high transcriptional activity, or through incrementally increasing 
copy number, represent sites of secondary selective pressure. Transcriptomic 
consequences range from strong individual oncogene effects through to weak 
but quantifiable multigene expression effects. We thus present a somatic 
rearrangement mutational process exerting its influence through coding 
sequences and non-coding regulatory elements, contributing a continuum of 
driver consequences, from modest through to strong effects, supporting a 
polygenic model of cancer development. 
 
 
 
 
Introduction 
 
Whole genome sequencing (WGS) has permitted unrestricted access to the 
human cancer genome, triggering the hunt for driver mutations that could confer 
selective advantage in all parts of human DNA. Recurrent somatic mutations in 
coding sequences are often interpreted as driver mutations particularly when 
supported by transcriptomic changes or functional evidence. However, recurrent 
somatic mutations in non-coding sequences are less straightforward to interpret. 
Although TERT promoter mutations in malignant melanoma1,2 and NOTCH1 3’ 
region mutations in chronic lymphocytic leukaemia3 have been successfully 
demonstrated as driver mutations, multiple non-coding loci have been 
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highlighted as recurrently mutated but evidence supporting these as true drivers 
remains lacking. Indeed, in a recent exploration of 560 breast cancer whole 
genomes4, the largest cohort of WGS cancers to date, statistically significant 
recurrently mutated non-coding sites (by substitutions and insertions/deletions 
(indels)) were identified but alternative explanations for localized elevation in 
mutability such as a propensity to form secondary DNA structures were 
observed4.  
 
These efforts have been focused on recurrent substitutions and indels and an 
exercise seeking sites that are recurrently mutated through rearrangements has 
not been formally performed. Such sites could be indicative of driver loci under 
selective pressure (such as amplifications of ERBB2 and CCND1) or could 
represent highly mutable sites that are simply prone to double-strand break 
(DSB) damage. Sites that are under selective pressure generally have a high 
incidence in a particular tissue-type, are highly complex and comprise multiple 
classes of rearrangement including deletions, inversions, tandem duplications 
and translocations. By contrast, sites that are simply breakable may show a low 
frequency of occurrence and demonstrate a preponderance of a particular class 
of rearrangement, a harbinger of susceptibility to a specific mutational process.  
 
An anecdotal observation in the cohort of 560 breast cancers was of sites in the 
genome that appeared to be rearranged recurrently, albeit at a low frequency, 
and by a very specific rearrangement class of tandem duplications. Rarely, 
tandem duplications recurred at approximately the same locus in the same 
cancer resulting in the appearance of nested tandem duplications. No 
explanation was provided for this observation. Here, we have taken a novel 
approach to systematically seek sites in the human cancer genome that are 
recurrently mutagenized by rearrangements, specifically tandem duplications, in 
order to fully understand the prevalence and the impact of these sites of 
recurrent tandem duplications in this cohort of breast cancers.  
 
In all, 77,695 rearrangements including 59,900 intra-chromosomal (17,564 
deletions, 18,463 inversions and 23,873 tandem duplications) and 17,795 inter-
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chromosomal translocations were identified in this cohort previously. The 
distribution of rearrangements within each cancer was complex (Figure 1A-D); 
some had few rearrangements without distinctive patterns, some had collections 
of focally occurring rearrangements such as amplifications, whereas many had 
rearrangements distributed throughout the genome - indicative of very different 
set of underpinning mutational processes. 
 
Thus, large, focal collections of “clustered” rearrangements were first separated 
from rearrangements that were widely distributed or “dispersed” in each cancer, 
then distinguished by class (inversion, deletion, tandem duplication or 
translocation) and size (1-10kb, 10-100kb, 100kb-1Mb, 1-10Mb, more than 
10Mb)4, before a mathematical method for extracting mutational signatures was 
applied5. Six rearrangement signatures were extracted (RS1-RS6) representing 
discrete rearrangement mutational processes in breast cancer4. Two distinctive 
mutational processes in particular were associated with dispersed tandem 
duplications. RS1 and RS3 are mostly characterized by large (>100kb) and small  
(< 10kb) tandem duplications, respectively (Figure 1E). Although both are 
associated with tumors that are deficient in homologous recombination (HR) 
repair4,6-9, RS3 is specifically associated with inactivation of BRCA1. Thus, 
because they represent distinct biological defects in human cells, we have chosen 
to proceed with a systematic analysis of sites of recurrent mutagenesis of these 
two mutational signatures as independent processes.  
 
Previously, tumors have been described as having a large degree of genomic 
instability10,11 and even a tandem duplicator phenotype12-14 but did not have the 
resolution to distinguish different tandem duplication signatures. Here, we show 
the importance of taking a mutational signatures approach, highlighting 
differences in behavior between short (<10kb) and long (>100kb) tandem 
duplications.  
 
We identified a surprising number of rearrangement hotspots dominated by the 
RS1 mutational process characterized by long (>100kb) tandem duplications4.  
Intuitively, a hotspot of mutagenesis that is enriched for a particular mutational 
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signature implies a propensity to DNA double-strand break (DSB) damage and 
specific recombination-based repair mutational mechanisms that could explain 
these tandem duplication hotspots. However, we find additional intriguing 
features associated with these hotspots that challenge current perceptions in 
cancer biology, explained below.  
 
 
Results 
 
Identification of rearrangement hotspots 
 
In order to systematically identify hotspots of tandem duplications through the 
genome, we first considered the background distribution of rearrangements that 
is known to be non-uniform. A regression analysis was performed to detect and 
quantify the associations between the distribution of rearrangements and a 
variety of genomic landmarks including replication time domains, gene-rich 
regions, background copy number, chromatin state and repetitive sequences 
(Online Methods Section 3 and Supplementary Figure S1). The associations 
learned were taken into consideration creating an adjusted background model 
and were also applied during simulations, these steps being critical to the 
following phase of hotspot detection. Adjusted background models and 
simulated distributions were calculated for RS1 and RS3 tandem duplication 
signatures separately because of vastly differing numbers of rearrangements in 
each signature of 5,944 and 13,498 respectively, which could bias the detection 
of hotspots for the different signatures.  
 
We next employed the principle of intermutation distance15 (IMD)- the distance 
from one breakpoint to the one immediately preceding it in the reference 
genome and used a piece-wise constant fitting (PCF) approach16,17, a method of 
segmentation of sequential data that is frequently utilized in analyses of copy 
number data.  PCF was applied to the IMD of RS1 and RS3 separately, seeking 
segments of the breast cancer genomes where groups of rearrangements 
exhibited short IMD, indicative of “hotspots” that are more frequently 
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rearranged than the adjusted background model (Figure 2, Supplementary 
Materials). The parameters used for the PCF algorithm were optimized against 
simulated data (Online Methods Section 5 and Supplementary Figure S2). We 
aimed to detect a conservative number of hotspots while minimising the number 
of false positive hotspots. Note that all highly clustered rearrangements such as 
those causing driver amplicons had been previously identified in each sample 
and removed, and thus do not contribute to these hotspots. However, to ensure 
that a hotspot did not comprise only a few samples with multiple breakpoints 
each, a minimum of eight samples was required to contribute to each hotspot. Of 
note, this method negates the use of genomic bins and permits detection of 
hotspots of varying genomic size. 
 
Thus, the PCF method was applied to RS1 and RS3 rearrangements separately, 
seeking loci that have a rearrangement density exceeding twice the local 
adjusted background density for each signature and involving a minimum of 
eight samples. Interestingly, 0.5% of 13,498 short RS3 tandem duplications 
contributed towards four RS3 hotspots. By contrast, 10% of 5,944 long RS1 
tandem duplications formed 33 hotspots demonstrating that long RS1 tandem 
duplications are 20 times more likely to form a rearrangement hotspot than 
short RS3 tandem duplications. Indeed, these were visible as punctuated 
collections of rearrangements in genome-wide plots of rearrangement 
breakpoints (Figure 2C and Supplementary Table S1).   
 
 
Contrasting RS3 hotspots to RS1 hotspots 
 
RS3 hotspots had different characteristics to that of RS1 hotspots. The four RS3 
hotspots were highly focused, occurred in small genomic windows and exhibited 
very high rearrangement densities (range 61.8 to 658.3 breakpoints per Mb 
(Figure 3B). In contrast, the 33 RS1 hotspots had densities between 7.6 and 83.2 
breakpoints per Mb and demonstrated other striking characteristics (Figure 3A). 
In several RS1 hotspots, duplicated segments showed genomic overlap between 
patients, even when most patients had only one tandem duplication, as depicted 
in a cumulative plot of duplicated segments for samples contributing 
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rearrangements to a hotspot (Figure 3C, Supplementary Figure S3).  
Interestingly, the nested tandem duplications that were observed incidentally in 
the past4, were a particular characteristic of RS1 hotspots.  The hotspots of RS1 
and RS3 were distinct from one another apart from one locus where two 
lncRNAs NEAT1 and MALAT1 reside (discussed in Section 3 of Supplementary 
Note).   
 
Assessing the potential genomic consequences of RS1 and RS3 tandem 
duplications on functional components of the genome12, RS1 rearrangements 
were observed to duplicate important driver genes and regulatory elements 
while RS3 rearrangements were found to mainly transect them (Figure 4, Online 
Methods Section 8, Supplementary Table S2). This is likely to be related to the 
size of tandem duplications in these signatures. Short (<10kb) RS3 tandem 
duplications are more likely to duplicate very small regions, with the effect 
equivalent of disrupting genes or regulatory elements. In contrast, RS1 tandem 
duplications are long (>100kb), and would be more likely to duplicate whole 
genes or regulatory elements.  
 
Strikingly, the effects were strongest for tandem duplications that contributed to 
hotspots of RS1 and RS3 than they were for tandem duplications that were not in 
hotspots or that were simulated. Thus, although the likelihood of 
transection/duplication may be governed by the size of tandem duplications, the 
particular enrichment for hotspots must carry important biological implications.  
 
The enrichment of disruption of tumor suppressor genes by RS3 hotspots (OR 
167, P=9.4 × 10-41 by Fisher’s exact test) and is relatively simple to understand - 
these are likely to be under selective pressure. Accordingly, two of the four RS3 
hotspots occurred within well-known tumor suppressors, PTEN and RB1. Other 
rearrangement classes are also enriched in these genes in-keeping with being 
driver events (Online Methods Section 7, Supplementary Table S3). Furthermore, 
these sites were identified as putative driver loci in an independent analysis 
seeking driver rearrangements through gene-based methods4.  
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By contrast, the enrichment of oncogene duplication by RS1 hotspots (OR 1.49, 
P=4.1 × 10-3  by Fisher’s exact test) was apparent12, although not as strong as the 
enrichment of transections of cancer genes by RS3 hotspots. More notably, the 
enrichment of other putative regulatory features was also observed. Indeed, we 
observed that susceptibility loci associated with breast cancer18,19 were 4.28 
times more frequent in an RS1 hotspot than in the rest of the tandem duplicated 
genome (P=3.4 × 10-4 in Poisson test, Supplementary Figure S4A, Supplementary 
Figure S5, Supplementary Figure S6). Additionally, 18 of 33 (54.5%) RS1 tandem 
duplication hotspots contained at least one breast super-enhancer. The density 
of breast super-enhancers was 3.54 times higher in a hotspot compared to the 
rest of the tandem duplicated genome (P=7.0 × 10-16 in Poisson test, 
Supplementary Figure S4B, Supplementary Figure S5, Supplementary Figure S6). 
This effect was much stronger than for non-breast tissue super-enhancers (OR 
1.62) or enhancers in general (OR 1.02, Supplementary Table S4). This gradient 
reinforces how the relationship between tandem duplication hotspots and 
regulatory elements deemed as super-enhancer, is tissue-specific. 
 
The reason underlying these observations in RS1 hotspots however is a little less 
clear. Single or nested tandem duplications in RS1 hotspots effectively increase 
the number of copies of a genomic region but only incrementally. The 
enrichment of breast cancer specific susceptibility loci, super-enhancers and 
oncogenes at hotspots of a very particular mutational signature could reflect an 
increased likelihood of damage and thus susceptibility to a passenger mutational 
signature that occurs because of the high transcriptional activity associated with 
such regions. However, it is also intriguing to consider that the resulting copy 
number increase could confer some more modest selective advantage and 
contribute to the driver landscape.  To investigate the latter possibility, we 
explored the impact of RS1 tandem duplications on gene expression. 
 
 
 
Impact of RS1 hotspots on expression 
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Several RS1 hotspots involved validated breast cancer genes12 (e.g. ESR1, 
ZNF217, Supplementary Figures S7,S8) and could conceivably contribute to the 
driver landscape through increasing the number of copies of a gene - even if by 
only a single copy.  
 
ESR1 is an example of a breast cancer gene that is a target of an RS1 hotspot. In 
the vicinity of ESR1 is a breast tissue specific super-enhancer and a breast cancer 
susceptibility locus. Fourteen samples contribute to this hotspot, of which ten 
have only a single tandem duplication or simple nested tandem duplications of 
this site. Six samples had expression data and all showed significantly elevated 
levels of ESR1 despite modest copy number increase (Supplementary Figure 
S7a). Four samples have a small number of rearrangements (< 30) yet have a 
highly specific tandem duplication of ESR1, suggestive of selection 
(Supplementary Figure S9). Most other samples with rearrangements in the 
other 32 hotspots were triple negative tumors. By contrast, samples with 
rearrangements in the ESR1 hotspot showed a different preponderance – eleven 
of fourteen were estrogen receptor positive tumors.  Thus we propose that the 
duplications in the ESR1 hotspot are putative drivers that would not have been 
detected using customary copy number approaches previously, but are likely to 
be important to identify because of the associated risk of developing resistance 
to anti-estrogen chemotherapeutics20,21. 
 
c-MYC encodes a transcription factor that coordinates a diverse set of cellular 
programs and is deregulated in many different cancer types22,23. 30 patients 
contributed to the RS1 hotspot at the c-MYC locus with modest copy number 
gains. A spectrum of genomic outcomes was observed including single or nested 
tandem duplications, flanking (16 samples) or wholly duplicating the gene body 
of c-MYC (14 samples) (Figure 5A). Notably, a breast tissue super-enhancer and 
two germline susceptibility loci lie in the vicinity of c-MYC 24 19(Figure 5B). We 
had a larger number of samples with corresponding RNA-seq data and thus 
modeled the expression levels of c-MYC taking breast cancer subtype, 
background copy number (whole chromosome arm gain is common for chr 8) 
and sought whether tandem duplicating a gene was associated with increased 
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transcription. We find that tandem duplications in the RS1 hotspot were 
associated with a doubling of   the expression level of c-MYC (0.99 s.e. 0.28 log2 
FPKM, P=4.4 × 10-4  in t-test)  (Supplementary Table S5, Supplementary Figure 
S10).  
 
The expression–related consequences of tandem duplications of putative 
regulatory elements however, is more difficult to assess because of the 
uncertainty of the downstream targets of these regulatory elements. We have 
thus taken a global gene expression approach and applied a mixed effects model 
to understand the contribution of tandem duplications of these elements, 
controlling for breast cancer subtype and background copy number. We find that 
tandem duplications involving a super-enhancer or breast cancer susceptibility 
locus are associated with an increase in levels of global gene expression even 
when the gene itself is not duplicated. The effect is strongest on oncogenes (0.30 
+- 0.20 log2 FPKM, P=0.12 in likelihood ratio test) than for other genes (0.16 s.e. 
0.04 log2 FPKM, P=1.8 × 10-4) within RS1 hotspots or for genes in the rest of the 
genome (Supplementary Table S4).  
 
Thus, tandem duplications of cancer genes demonstrate strong expression 
effects in individual genes (e.g. ESR1 and c-MYC) while tandem duplications of 
putative regulatory elements demonstrate modest but quantifiable global gene 
expression effects. The spectrum of functional consequences at these loci could 
thus range from insignificance, through mild enhancement, to strong selective 
advantage – consequences of the same somatic rearrangement mutational 
process.  
 
 
Long tandem duplication hotspots are present and distinct in other cancers 
 
We additionally explored other cancer cohorts where sequence files were 
available. Two cancer types are known to exhibit tandem duplications, 
particularly pancreatic and ovarian cancers. Raw sequence files were parsed 
through our mutation-calling algorithms and rearrangement signatures 
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extracted as for breast cancers. Adjusted background models and simulations 
were performed on these new datasets separately. The total numbers of 
available samples (73 ovarian and 96 pancreatic)10,11 were much smaller than 
the breast cancer cohort, which is currently the largest cohort of WGS cancers of 
a single cancer type in the world. Thus power for detecting hotspots was 
substantially reduced particularly for pancreatic cancer (Supplementary Figure 
11 for power calculation). Nevertheless, in ovarian tumors 2,923 RS1 
rearrangements were found and seven RS1 hotspots identified (Supplementary 
Table S6), of which six were distinct from breast cancer RS1 hotspots. A marked 
enrichment for ovarian cancer specific super-enhancers (11 super-enhancers 
over 20.2 Mb, OR 2.9, P=1.9 × 10-3 in Poisson test) was also noted for these 
hotspots. MUC1, a validated oncogene in ovarian cancer was the focus at one of 
the hotspots. Thus, although we require larger cohorts of WGS cancers in the 
future to be definitive, the presentiment is that different cancer-types could have 
different RS1 hotspots that are focused at highly transcribed sites specific to 
different tissues. 
 
Discussion: Selective susceptibility or selective pressure? 
 
Rearrangement signatures may, in principle, be mere passenger read-outs of the 
stochastic mayhem in cancer cells. However, mutational signatures recurring at 
specific genomic sites, which also coincide with distinct genomic features, 
suggest a more directed nature – a sign of either selective susceptibility or 
selective pressure. 
 
Perhaps it is an attribute of being more highly active or transcribed (e.g. super-
enhancers) or some other as yet unknown quality (e.g. germline SNP sites and 
other hotspots with no discerning features), these hotspots exemplify loci that 
are rendered more available for DSB damage and more dependent on repair that 
generates large tandem duplications6,25-27. They signify genomic sites that are 
innately more susceptible to the HR-deficient tandem duplication mutational 
process – sites of selective susceptibility.  
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An alternative argument could also hold true: It could be that the likelihood of 
damage/repair relating to this mutational process is similar throughout the 
genome. However, through incrementally increasing the number of copies of 
coding genes that drive tissue proliferation, survival and invasion (ESR1, 
ZNF217) or non-coding regions that have minor or intermediate modifying 
effects in cancer such as germline susceptibility loci or super-enhancer elements, 
long tandem duplications (unlike other classes of rearrangements) could 
specifically enhance the overall likelihood of carcinogenesis. The profound 
implication is that these loci do come under a degree of selective pressure, and 
that this HR-deficient tandem duplication mutational process is in fact a novel 
mechanism of generating secondary somatic drivers.  
 
Functional activity related to being a super-enhancer or SNP site could underlie 
primary susceptibility to mutagenesis of a given locus, but it requires a repair 
process that generates large tandem duplications to confer selective advantage 
(Figure 5C). Tandem duplication mutagenesis is associated with DSB repair in 
the context of HR deficiency and is a potentially important mutagenic mechanism 
driving genetic diversity in evolving cancers by increasing copy number of 
portions of coding and non-coding genome. It could directly increase the number 
of copies of an oncogene or alter non-coding sites where super-enhancers/risk 
loci28 are situated. It could therefore produce a spectrum of driver 
consequences29,30, ranging from strong effects in coding sequences to weaker 
effects in the coding and non-coding genome, profoundly, supporting a polygenic 
model of cancer development.  
 
 
Conclusions 
 
Structural mutability in the genome is not uniform. It is influenced by forces of 
selection and by mutational mechanisms, with recombination-based repair 
playing a critical role in specific genomic regions.  Mutational processes may 
however not simply be passive contrivances. Some are possibly more harmful 
than others. We suggest that mutation signatures that confer a high degree of 
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genome-wide variability are potentially more deleterious for somatic cells and 
thus more clinically relevant. Translational efforts should be focused on 
identifying and managing these adverse mutational processes in human cancer.  
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Figure legends 
 
Figure 1: Spectrum of distribution of rearrangements in human breast 
cancers. Circos plots depicting somatic rearrangements with chromosomal 
ideogram on the outermost right and lines representing rearrangements 
(green=tandem duplications, orange=deletions, blue=inversions and 
gray=interchromosomal events). A, quiescent tumor, B, tumor with focal 
“clustered” rearrangements, C, tumor with mainly tandem duplications 
distributed throughout the genome (“dispersed” rearrangements) D, tumor with 
a mixed pattern of dispersed rearrangements and clustered rearrangements. E, 
Rearrangement Signatures 1 and 3 comprise mainly tandem duplications but are 
characterized predominantly by tandem duplications of different lengths 
(>100kb and <10kb respectively). 
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Figure 2: Identifying hotspots of rearrangements. A, A schematic of dispersed 
rearrangements in the genomes of 5 hypothetical patients, with regions that are 
identified as hotspots by the PCF algorithm highlighted in beige. Note the 
differing sizes of each putative hotspot permitted through this method that 
negates the use of bins. B, Workflow of PCF application to rearrangement 
signatures. C, Rainfall plots of chromosome 8 rearrangements for tandem 
duplication signatures RS1 (>100kb) top panel and RS3 (<10kb) bottom panel. 
Inter-rearrangement distance is plotted on a log-scale on the y-axis. Black lines 
demonstrate PCF-defined hotspots. RS1 is 20 times more likely to form hotspots 
than RS3 and these are visible as punctuated collections of breakpoints in these 
plots.    
 
Figure 3: Hotspots of dispersed rearrangements: A large (>100kb) tandem 
duplication mutational process shows distinctive genomic overlap between 
patients and coincides with germline susceptibility loci and super-
enhancer regulatory elements 
A, A summary of 33 hotspots of long tandem duplications (RS1) and, B, 4 
hotspots of short tandem duplications (RS3). Higher panel shows density of 
rearrangement breakpoints within hotspots, and their positions on 
chromosomes. The black horizontal lines denote the expected breakpoint 
density according to the background model. Lower panel shows frequency of 
each hotspot in the cohort of 560 patients. Hotspots that contain breast cancer 
susceptibility SNPs are marked with blue circles, and breast-specific super-
enhancers marked with red triangles. Genes that may be relevant are highlighted 
although their true significance is uncertain. C, Two different hotspots of RS1: 
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left panel (chr12:11.8Mb-12.8Mb) coincides with two breast tissue specific 
super-enhancers and right panel (chr8:116.6Mb-117.7Mb) coincides with a 
germline susceptibility locus of breast cancer. Nearby cancer genes are 
annotated, although relevance of these genes is uncertain. Next six panels depict 
genomic rearrangements for six individual patients at each locus. Copy number 
(y-axis) depicted as black dots (10kb bins). Green lines present tandem 
duplication breakpoints. Note the precise genomic overlap between patients.  
Lowermost panel presents cumulative number of samples with a rearrangement 
involving this genomic region, emphasizing at its peak, the region of critical 
genomic overlap between samples. Thick red lines represent breast-tissue 
specific super enhancers. Blue vertical line represents position of germline 
susceptibility locus of breast cancer. Relevant SNP rsID is provided.  
 
Figure 4: Genomic consequences of the tandem duplication signatures 
Tandem duplications can transect or duplicate genomic features like regulatory 
elements or genes. A, tandem duplications attributed to rearrangement 
signature RS1 often duplicate genomic regions containing breast cancer 
predisposition SNPs, breast tissue super-enhancers and oncogenes. RS1 
rearrangements in hotspots show a particular enrichment when compared to 
RS1 rearrangements that occur in other regions and when compared to 
simulated rearrangements.  There are 524 RS1 duplications in hotspots, and 
4,916 duplications outside of hotspots. B, tandem duplications attributed to RS3 
in hotspots are enriched for transecting cancer genes more than in the rest of 
genome, or in simulated data. There are 57 RS3 duplications in hotspots, and 
10,967 RS3 duplications outside of hotspots. Asterisks highlight statistically 
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significant enrichment of any particular genomic feature within hotspots 
compared to outside hotspots, as calculated by two-sided Fisher’s exact test. 
Four asterisks **** denote p-value P<= 0.0001, ** P<=0.01, * P<=0.05 . Error bars 
show the standard deviation across ten different simulated datasets. 
 
Figure 5: From selective susceptibility to selective pressure 
A, The spectrum of genomic structural variation at a single locus: c-MYC. Copy 
number (y-axis) depicted as black dots (10kb bins). Lines represent 
rearrangement breakpoints (green= tandem duplications, pink=deletions, 
blue=inversions and purple=interchromosomal events). Genes other than c-MYC 
were marked as black lines at the top of the panel. B, Cumulative number of 
samples with dispersed rearrangements within the c-MYC-related tandem 
duplication hotspot. A peak is observed very close to c-MYC but also flanking c-
MYC where two germline susceptibility loci are observed. A large super-
enhancer is also situated upstream of c-MYC. C, Putative model of cascade of 
events underlying the RS1-enriched hotspots in breast cancer. Sites enriched for 
super-enhancers (SENH) may be more highly transcribed and thus exposed to 
damage including DSB damage. Long tandem duplications are particularly at risk 
of copying whole genes in contrast to other rearrangement classes. Thus 
although other rearrangement classes may be found (in low numbers in the 
same region), an enrichment of long tandem duplications is observed because of 
a small degree of selection in action.  
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Online Methods 
 
1. Dataset 
 
The primary dataset was obtained from another publication 4. Briefly, 560 
matched tumor and normal DNAs were sequenced using Illumina sequencing 
technology, aligned to the reference genome and mutations called using a suite 
of somatic mutation calling algorithms as defined previously. In particular, 
somatic rearrangements were called via BRASS (Breakpoint AnalySiS) 
(https://github.com/cancerit/BRASS) using discordantly mapping paired-end 
reads for the discovery phase. Clipped reads were not used to inform discovery. 
Primary discovery somatic rearrangements were filtered against the germline 
copy number variants (CNV) in the matched normal, as well as a panel of fifty 
normal samples from unrelated samples to reduce the likelihood of calling 
germline CNVs and to reduce the likelihood of calling false positives. 
 
In silico and /or PCR-based validation were performed in a subset of samples 4.  
Primers were custom-designed and potential rearrangements were PCR-
amplified and identified as putatively somatic if a band observed on gel 
electrophoresis was seen in the tumour and not in the normal, in duplicate. 
Putative somatic rearrangements were then verified through capillary-
sequencing. Amplicons that were successfully sequenced were aligned back to 
the reference genome using Blat, in order to identify breakpoints to basepair 
resolution. Alternatively, an in silico analysis was performed using local 
reassembly. Discordantly mapping read pairs that were likely to span 
breakpoints as well as a selection of nearby properly paired reads, were grouped 
for each region of interest.  Using the Velvet de novo assembler 31, reads were 
locally assembled within each of these regions to produce a contiguous 
consensus sequence of each region. Rearrangements, represented by reads from 
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the rearranged derivative as well as the corresponding non-rearranged allele 
were instantly recognisable from a particular pattern of five vertices in the de 
Bruijn graph (a mathematical method used in de novo assembly of (short) read 
sequences) of component of Velvet. Exact coordinates and features of junction 
sequence (e.g. microhomology or non-templated sequence) were derived from 
this, following aligning to the reference genome, as though they were split reads. 
 
Only rearrangements that passed the validation stage were used in these 
analyses. Furthermore, additional post-hoc filters were included to remove 
library-related artefacts (creating an excess of inversions in affected samples).  
 
 
2. Rearrangement signatures 
 
Previously, we had classified rearrangements as mutational signatures as 
extracted using the Non-Negative Marrix Factorization framework.  
 
Briefly, we first separated rearrangements that were focally clustered from 
widely dispersed rearrangements because we reasoned that the underlying 
biological  processes that generates these different rearrangement distributions 
are likely to be distinct. A piecewise constant fitting (PCF) approach was applied 
in order to distinguish focally clustered rearrangements from dispersed ones. 
For each sample, both breakpoints of each rearrangement were considered 
separately from one another and all breakpoints were ordered by chromosomal 
position. The inter-rearrangement distance, defined as the number of base pairs 
from one rearrangement breakpoint to the one immediately preceding it in the 
reference genome, was calculated. Putative regions of clustered rearrangements 
were identified as having an average inter-rearrangement distance that was at 
least 10 times greater than the whole genome average for the individual sample. 
PCF parameters used were γ = 25 and kmin = 10. The respective partner 
breakpoint of all breakpoints involved in a clustered region are likely to have 
arisen at the same mechanistic instant and so were considered as being involved 
in the cluster even if located at a distant chromosomal site. 
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In both classes of rearrangements, clustered and non-clustered, rearrangements 
were subclassified into deletions, inversions and tandem duplications, and then 
further subclassified according to size of the rearranged segment (1-10kb, 10kb-
100kb, 100kb-1Mb, 1Mb-10Mb, more than 10Mb).  The final category in both 
groups was interchromosomal translocations. The classification produces a 
matrix of 32 distinct categories of structural variants across 544 breast cancer 
genomes. This matrix was decomposed using the previously developed approach 
for deciphering mutational signatures by searching for the optimal number of 
mutational signatures that best explains the data 5.  A rearrangement was 
attributed to a signature if the posterior probability for the rearrangement to be 
generated by the signature in a given sample exceeded 0.58. 
 
In all, six different rearrangement signatures were identified. Rearrangement 
Signatures 1 and 3 were two signatures that were particularly characterised by 
tandem duplications (Main Figure 1E).  
 
Rearrangement signature 1 (RS1) is characterized mainly by large tandem 
duplications (>100kb) while rearrangement signature 3 (RS3) is characterised 
mainly by short tandem duplications. There is good reason to believe that these 
signatures are biologically distinct entities as RS3 is very strongly associated 
with BRCA1 abrogation (germline or somatic mutation or promoter 
hypermethylation with concurrent loss of the wild-type allele). BRCA1 tumours 
also contain moderate numbers of RS1, but there are also samples with a larger 
excess of RS1 rearrangements that do not carry a specific genetic abnormality 4. 
 
In order to perform a systematic survey of tandem duplication hotspots, we 
focused on these two rearrangements signatures. However, tandem duplications 
(and other rearrangements) are also not uniformly distributed through the 
genome. Thus, the following sections describe how we detect hotspots of tandem 
duplications of RS1 and RS3, after correcting for genomic biases. 
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3. Modelling the background distribution of rearrangements 
 
Rearrangements are known to have an uneven distribution in the genome. There 
have been numerous descriptions linking genomic features such as replication 
timing with the non-uniform distribution of rearrangements. Thus, any analysis 
that seeks to detect regions of higher mutability than expected must take the 
genomic features that influence this non-uniform distribution into account in its 
background model. In order to formally detect and quantify associations 
between genomic features and somatic rearrangements in breast cancer, we 
conducted a multi-variate genome-wide regression analysis. Please see Section 1 
in Supplementary Note for details. 
 
4. Simulations of rearrangements 
 
Simulations consisted of as many rearrangements as was observed for each 
sample in the dataset, preserving the type of rearrangement (tandem 
duplication, inversion, deletion or translocation), the length of each 
rearrangement (distance between partner breakpoints) and ensuring that both 
breakpoints fell within mappable/callable regions in our pipeline. Simulations 
also took into account the genomic bias of rearrangements that were identified 
above. Please see Section 2 in Supplementary Note for details. 
 
5. Optimization of the PCF algorithm 
 
The PCF (Piecewise-Constant-Fitting) algorithm is a method of segmentation of 
sequential data. We used PCF to find segments of the genome that had a much 
higher rearrangement density than the neighbouring genomic regions, and 
higher than expected according the background model. We show the significance 
of the identified hotspots by applying the same method to simulated data 
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(Section 4) that follows the known genomic biases of rearrangements like 
replication time domains, transcription and background copy number status. 
 
Each rearrangement has two breakpoints and these breakpoints were treated 
independently of each other. Breakpoints were sorted according to reference 
genome coordinates and an intermutation distance (IMD) between two genome-
sorted breakpoints was calculated for each breakpoint, then log-transformed to 
base 10. Log 10 IMD were fed into the PCF algorithm.  
 
In order to call a segment of a genome that has a higher rearrangement density 
as a “hotspot”, a number of parameters had to be determined. The smoothness of 
segmentation is determined by the gamma () parameter of the PCF analysis. A 
segment of genome was only considered a peak if it had a sufficient number of 
mutations, as specified by kmin. The average inter-mutation distance in the 
segment had to exceed an inter-mutation distance factor (i), which is the 
threshold when comparing breakpoint density in a segment to genome-wide 
density of breakpoints:  
 
𝑑𝑠𝑒𝑔
𝑑𝑏𝑔
> 𝑖 
 
where: 
𝑑𝑠𝑒𝑔 is the density of breakpoints in a segment defined as: 
𝑑𝑠𝑒𝑔 = (number of breakpoints in segment)/(length in bp of a segment) 
𝑑𝑏𝑔 is the expected density of breakpoints in the segment, given the background 
model from Section 3, which includes the genomic covariates of the segment. 
More specifically, 
𝑑𝑏𝑔 = (∑ 𝑏𝑖
𝑛
𝑖=1 )/(n ∗ s), where 𝑏𝑖 is the expected number of breakpoints in the 
bins overlapping the segment, n is the number of overlapping bins, and s is bin 
size (0.5 Mb). 
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The choice of parameters kmin,  and i for the PCF algorithm was based on 
training on the observed data and comparing the outcomes with that of the 
simulated data. 
 
Combinations of  and i were explored to determine the optimal parameters for 
detection of hotspots where the sensitivity of detection of every hotspot in 
observed data was balanced against the detection of false positive hotspots in 
simulated datasets (Supplementary Figure S2). This was quantified according to 
the false discovery rate.   
 
 
Based on the number of detected hotspots on observed and simulated data, we 
used the =8 and i=2 in the final analyses which results in 33 hotspots of RS1 and 
4 of RS3. In further 1000 simulated datasets the same parameters resulted on 
average in 3.3 (standard deviation 1.9) and 0.1 (standard deviation 0.3) hotspots 
respectively.   
 
A dataset that is not “clean” and that contains a lot of false positive 
rearrangements could result in the identification of hotspots of false positives. 
Thus, it is imperative to have a set of high quality, highly curated rearrangement 
data – with a better specificity than sensitivity – in order to avoid calling loci 
where algorithms have a tendency to miscall rearrangements, as hotspots.  
 
6. Workflow 
 
Six rearrangement signatures were extracted from this dataset of 560 breast 
tumours as previously described (Section 2). Each rearrangement was 
probabilistically assigned to each rearrangement signature given the six 
rearrangement signatures and the estimated contribution of each signature to 
each sample 4. 
 
To define hotspots of rearrangements in RS1 and RS3, the PCF algorithm was 
applied to the log10 IMD of RS1 or RS3 breakpoints separately using the 
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following parameters: = 8, kmin = 8 and i = 2. Each locus was required to be 
represented by 8 or more samples.  The section below describes the hotspots 
that were identified by this method. 
 
7. Identifying hotspots for individual rearrangement signatures  
 
To explore hotspots associated with signatures of tandem duplications, we first 
separated rearrangements associated with the two signatures that are strongly 
characterised by tandem duplications (RS1 and RS3) (Main Figure 2). PCF was 
performed on each of these two categories. 33 hotspots of long RS1 tandem 
duplications were identified and 4 hotspots of short RS3 tandem duplications 
were seen, and they are listed and annotated in Supplementary Table S1.  
 
RS3 characterised by short tandem duplications also demonstrated 4 hotspots, 
two were likely drivers (PTEN, RB1) and the significance of the other two are less 
clear (CDK6 and NEAT1/MALAT1).  The interpretation of duplications at the 
NEAT1/MALAT1 locus is provided in Supplementary Note Section 3. 
 
For hotspots of remaining rearrangement signatures please see the 
Supplementary Note Section 4. 
 
8. Genomic consequences of tandem duplications 
 
We assessed the potential genomic consequences of the two rearrangement 
signatures associated with tandem duplications on gene function and on 
regulatory elements. 
 
Rearrangements associated with the RS1 signature are usually long tandem 
duplications (>100kb). These are more likely to duplicate whole genes and 
whole super-enhancer regulatory elements. In contrast, rearrangements 
associated with the RS3 signature are usually short tandem duplications 
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(<10kb), and therefore more likely to duplicate smaller regions which could have 
an effect equivalent of transecting genes or regulatory elements.  
 
To formally assess the potential genomic consequences of RS1 and RS3 tandem 
duplications on gene function and on regulatory elements, we explored the 
following genomic elements: 
 
 breast cancer susceptibility SNPs 
 breast-tissue specific super-enhancer regulatory elements  
 oncogenes (if a duplications covers both a super-enhancer and an 
oncogene, it will be counted in both categories) 
 tumour suppressor genes 
 all genes 
 
An element was considered as wholly duplicated by a tandem duplication if the 
element was completely between the two breakpoints. An element was 
considered as transected by a tandem duplication if one or both breakpoints lay 
within the element. 
We did not consider the events where only one breakpoint of duplication was 
within an element, as the effect of such events on genes and other elements is 
unclear. 
 
We counted the number of times each of the five elements noted above was 
duplicated or transected for RS1 and RS3 respectively for: 
 RS1 or RS3 tandem duplications in hotspots (counted only once per 
sample – even if there are multiple tandem duplications affecting the 
same locus in the same person),  
 RS1 or RS3 tandem duplications that are not within hotspots,  
 RS1 and RS3 tandem duplications that have been simulated correcting for 
all the characteristics described above.  
 
Strikingly, RS1 hotspots are clearly enriched for duplicating whole oncogenes 
and whole super-enhancers, compared to RS1 rearrangements that are not 
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within hotspots and simulated RS1 rearrangements (Main Figure 4, 
Supplementary Table 3). This enrichment is not observed for RS3 hotspots. 
Furthermore, RS1 hotspot tandem duplications hardly ever transect genes or 
regulatory elements. In contrast, RS3 hotspots are strongly enriched for gene 
transections in-keeping with being driver loci.  
 
Thus here we provide evidence for different genomic consequences – whole 
gene/regulatory element duplications versus transections - given hotspots 
generated through different types of rearrangements, long or short tandem 
duplications.  
 
9. Germline loci of susceptibility to breast cancer 
 
The list of breast cancer germline susceptibility alleles was derived from the 
literature 18,32-40. This analysis is aimed at trying to determine whether there is 
an enrichment for breast cancer susceptibility SNP alleles in breast cancer, to 
quantify this relationship and provide a measure of statistical significance. 
 
We performed an analysis that compares the density of SNPs in the genomic 
footprint of RS1 hotspots against the genomic footprint of other RS1 
rearrangements in general (instead of simply to the rest of genome) – this 
controls for the unevenness in the distribution of tandem duplications. RS1 
hotspots encompass 58Mb of the genome while other segments of the genome 
covered by (at least) one tandem duplication encompasses 2,106Mb.   
 
The density of breast cancer susceptibility SNPs outside of RS1 hotspots was 
0.036 per Mb. Within RS1 hotspots, there were 9 breast cancer susceptibility 
SNPs or 0.16 SNPs per Mb. Thus, the odds ratio (OR) of finding a breast cancer 
susceptibility SNP in RS1 hotspots compared to tandem duplicated regions 
outside of RS1 hotspots is 4.28 (P=3.4× 10-4 Poisson one-sided).  
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The Poisson test was used in order to compare rates of events between genomic 
regions of different sizes, and to account for uncertainty that comes from low 
number of events (9 SNPs) falling into the hotspots. 
 
 
10. Enrichment for regulatory elements 
 
The super-enhancer dataset was obtained from Super-Enhancer Archive (SEA)40. 
This archive uses publicly available H3K27ac Chip-seq datasets and published 
super-enhancers lists to produce a comprehensive list of super-enhancers in 
multiple cell types/tissues.  From this list (containing 2,282 unique super-
enhancers for 15 human cell types/tissues), we extracted the super-enhancers 
active in breast cancer (755 elements) and the super-enhancers active in the 
other cell types/tissues (1,528 elements). Regulatory elements were mutually 
exclusive to each list to ensure that each super-enhancer was analyzed only in 
one category, and a super-enhancer was placed in the breast cancer category 
where there was experimental evidence for multiple activations. 
  
The list of general enhancers was obtained from Ensembl Regulatory Build 
(GRCh37)41. We used the “Multicell” list containing 139,204 elements active in 
17 different cell lines. From this list, we filtered out the enhancers that 
overlapped with super-enhancers, and we obtained a final list composed of 
136,858 regulatory elements.  
 
As described in the previous section, we divided the genome into RS1 hotspots 
(58Mb), and other segments of the genome covered by a minimum of a single 
tandem duplication (2,106Mb).  We compared the density of super-enhancers 
within RS1 hotspot segments and outside of the hotspots (Supplementary Figure 
S4). 
 
Method 1: 
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The OR of finding a super-enhancer active in breast tissue in RS1 hotspots, 
compared to regions of the genome rarely covered by RS1 duplications is 3.54 
(Poisson one-sided test P=7.0 × 10-16). The OR for observing a super-enhancers 
that is not associated with breast tissue is lower at 1.62, with P=6.4× 10-4. The 
OR for finding any enhancer in an RS1 hotspots is 1.02, with a p-value of 0.12.  
 
 Method 2: 
 
The assumption made in the above analysis is that super-enhancers follow a 
Poisson distribution, which could be violated by clusters of super-enhancer 
elements that exist in the genome. We thus performed a set of simulations that 
do not depend on these assumptions. 
 
In order to assess the likelihood of observing 59 super-enhancers within the 
regions of RS1 hotspots, the same number of regions of equivalent sizes was 
sampled from the genome. Similarly as in the previous analysis, the random 
segments of the genome were drawn from genomic regions representative of 
non-hotspot tandem duplications (2,106Mb). The procedure was repeated 
10,000 times and super-enhancers falling into the simulated segments were 
counted.  
 
The observed overlap with 59 or more super-enhancers occurred zero times in 
10,000 simulation rounds, by which we estimate the p-value of the observation 
to be P<10-4.  Figure S4C shows the empirical distribution observed in the 
simulations. 
 
11. Analysis of gene expression 
 
RNA expression levels of genes in the samples were obtained from RNA-seq data 
as reported by another publication 4.   We set out to assess whether tandem 
duplications in the hotspots are associated with increased expression of affected 
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genes. Statistical methods and results are presented in Supplementary Note 
Section 5. 
 
12. Hotpots of RS1 in other tumours 
 
In addition to breast cancer, tumours of other tissue types sometimes show 
excess of tandem duplications in their genomes. In order to investigate whether 
the rearrangements in other tumor types also accumulate in hotspots, we 
utilized previously published sequences of ovarian and pancreatic cancer 
genomes. Please see Supplementary Note Section 6. 
 
 
13. Data reporting 
 
No statistical methods were used to predetermine sample size. The experiments 
were not randomised and the investigators were not blinded to allocation during 
experiments as this was not relevant to the study. 
 
REFERENCES 
 
1. Huang, F.W. et al. Highly recurrent TERT promoter mutations in human 
melanoma. Science 339, 957-9 (2013). 
2. Vinagre, J. et al. Frequency of TERT promoter mutations in human 
cancers. Nat Commun 4, 2185 (2013). 
3. Puente, X.S. et al. Non-coding recurrent mutations in chronic lymphocytic 
leukaemia. Nature 526, 519-24 (2015). 
4. Nik-Zainal, S. Landscape of somatic mutations in 560 whole-genome 
sequenced breast cancers. (2016). 
5. Alexandrov, L.B. et al. Signatures of mutational processes in human 
cancer. Nature 500, 415-21 (2013). 
6. Mehta, A. & Haber, J.E. Sources of DNA double-strand breaks and models 
of recombinational DNA repair. Cold Spring Harb Perspect Biol 6, a016428 
(2014). 
7. Ceccaldi, R., Rondinelli, B. & D'Andrea, A.D. Repair Pathway Choices and 
Consequences at the Double-Strand Break. Trends Cell Biol 26, 52-64 
(2016). 
8. Morganella, S. et al. The topography of mutational processes in breast 
cancer genomes. Nature communications 7(2016). 
Hotspots.Glodzik.Manuscript.postRV.NG.v3
   
 
 33 
9. Helleday, T., Eshtad, S. & Nik-Zainal, S. Mechanisms underlying mutational 
signatures in human cancers. Nat Rev Genet 15, 585-98 (2014). 
10. Waddell, N. et al. Whole genomes redefine the mutational landscape of 
pancreatic cancer. Nature 518, 495-501 (2015). 
11. Patch, A.M. et al. Whole-genome characterization of chemoresistant 
ovarian cancer. Nature 521, 489-94 (2015). 
12. Menghi, F. et al. The tandem duplicator phenotype as a distinct genomic 
configuration in cancer. Proc Natl Acad Sci U S A 113, E2373-82 (2016). 
13. McBride, D.J. et al. Tandem duplication of chromosomal segments is 
common in ovarian and breast cancer genomes. J Pathol 227, 446-55 
(2012). 
14. Stephens, P.J. et al. Complex landscapes of somatic rearrangement in 
human breast cancer genomes. Nature 462, 1005-10 (2009). 
15. Nik-Zainal, S. et al. Mutational processes molding the genomes of 21 
breast cancers. Cell 149, 979-93 (2012). 
16. Nilsson, B., Johansson, M., Heyden, A., Nelander, S. & Fioretos, T. An 
improved method for detecting and delineating genomic regions with 
altered gene expression in cancer. Genome Biol 9, R13 (2008). 
17. Nilsen, G. et al. Copynumber: Efficient algorithms for single- and multi-
track copy number segmentation. BMC Genomics 13, 591 (2012). 
18. Garcia-Closas, M. et al. Genome-wide association studies identify four ER 
negative-specific breast cancer risk loci. Nat Genet 45, 392-8, 398e1-2 
(2013). 
19. Easton, D.F. et al. Genome-wide association study identifies novel breast 
cancer susceptibility loci. Nature 447, 1087-93 (2007). 
20. Li, S. et al. Endocrine-therapy-resistant ESR1 variants revealed by 
genomic characterization of breast-cancer-derived xenografts. Cell Rep 4, 
1116-30 (2013). 
21. Robinson, D.R. et al. Activating ESR1 mutations in hormone-resistant 
metastatic breast cancer. Nat Genet 45, 1446-51 (2013). 
22. Soucek, L. et al. Modelling Myc inhibition as a cancer therapy. Nature 455, 
679-83 (2008). 
23. Shi, J. et al. Role of SWI/SNF in acute leukemia maintenance and 
enhancer-mediated Myc regulation. Genes Dev 27, 2648-62 (2013). 
24. Zhang, X. et al. Identification of focally amplified lineage-specific super-
enhancers in human epithelial cancers. Nat Genet 48, 176-82 (2016). 
25. Costantino, L. et al. Break-induced replication repair of damaged forks 
induces genomic duplications in human cells. Science 343, 88-91 (2014). 
26. Willis, N.A., Rass, E. & Scully, R. Deciphering the Code of the Cancer 
Genome: Mechanisms of Chromosome Rearrangement. Trends Cancer 1, 
217-230 (2015). 
27. Saini, N. et al. Migrating bubble during break-induced replication drives 
conservative DNA synthesis. Nature 502, 389-92 (2013). 
28. Sloan, C.A. et al. ENCODE data at the ENCODE portal. Nucleic Acids Res 44, 
D726-32 (2016). 
29. Castro-Giner, F., Ratcliffe, P. & Tomlinson, I. The mini-driver model of 
polygenic cancer evolution. Nat Rev Cancer 15, 680-5 (2015). 
30. Roy, A. et al. Recurrent internal tandem duplications of BCOR in clear cell 
sarcoma of the kidney. Nat Commun 6, 8891 (2015). 
Hotspots.Glodzik.Manuscript.NG.Rev.v3  
 
 34 
31. Zerbino, D.R. & Birney, E. Velvet: algorithms for de novo short read 
assembly using de Bruijn graphs. Genome Res 18, 821-9 (2008). 
32. Cox, A. et al. A common coding variant in CASP8 is associated with breast 
cancer risk. Nat Genet 39, 352-8 (2007). 
33. Easton, D.F. et al. A systematic genetic assessment of 1,433 sequence 
variants of unknown clinical significance in the BRCA1 and BRCA2 breast 
cancer-predisposition genes. Am J Hum Genet 81, 873-83 (2007). 
34. Ahmed, S. et al. Newly discovered breast cancer susceptibility loci on 
3p24 and 17q23.2. Nat Genet 41, 585-90 (2009). 
35. Michailidou, K. et al. Genome-wide association analysis of more than 
120,000 individuals identifies 15 new susceptibility loci for breast cancer. 
Nat Genet 47, 373-80 (2015). 
36. Siddiq, A. et al. A meta-analysis of genome-wide association studies of 
breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. 
Hum Mol Genet 21, 5373-84 (2012). 
37. Stacey, S.N. et al. Common variants on chromosome 5p12 confer 
susceptibility to estrogen receptor-positive breast cancer. Nat Genet 40, 
703-6 (2008). 
38. Thomas, G. et al. A multistage genome-wide association study in breast 
cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). 
Nat Genet 41, 579-84 (2009). 
39. Turnbull, C. et al. Genome-wide association study identifies five new 
breast cancer susceptibility loci. Nat Genet 42, 504-7 (2010). 
40. Wei, Y. et al. SEA: a super-enhancer archive. Nucleic Acids Res 44, D172-9 
(2016). 
41. Zerbino, D.R., Wilder, S.P., Johnson, N., Juettemann, T. & Flicek, P.R. The 
ensembl regulatory build. Genome Biol 16, 56 (2015). 
 
